

salmeterol 25 mcg inhaler (Serevent Evohaler[®]) (No. 292/06)
GlaxoSmithKline

Product Update

7 July 2006

The Scottish Medicines Consortium has completed its assessment of the above product and advises Area Drug and Therapeutic Committees on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission.

Salmeterol 25 micrograms inhaler (Serevent Evohaler[®]) is accepted for use in NHS Scotland for the regular symptomatic treatment of reversible airways obstruction in patients with asthma, including those with nocturnal asthma or chronic obstructive pulmonary disease. It may also be used for the prevention of exercise-induced asthma.

Where the use of this long-acting beta agonist by aerosol inhalation is appropriate, it offers a chlorofluorocarbon (CFC)-free option at no additional cost.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 16 June 2006.

**Vice Chairman,
Scottish Medicines Consortium**